Perianal Crohn’s disease: A review

References

• Tarrant KM, Barclay ML, Frampton CMA, Gearry RB. Perianal disease predicts changes in Crohn’s disease phenotype- results of a population –based study of Inflammatory bowel disease phenotype. Am J Gastroenterol 2008;103:3082–93
   PubMed Web of Science ®Google Scholar
• American Gastroenterological Association Clinical Practice Committee. American Gastroenterological Association Medical Position Statement: Perianal Crohn’s Disease. Gastroenterology 2003;125:1503–7
   PubMed Web of Science ®Google Scholar
• Tozer PJ, Whelan K, Phillips RKS, Hart A. Etiology of perianal Crohn’s disease: role of genetic, microbiological, and immunological factors. Inflamm Bowel Dis 2009;15:1591–8
   Web of Science ®Google Scholar
• Williams JA. The place of surgery in Crohn’s disease. Gut 1971;12:739–49
   Google Scholar
• Williams DR, Coller JA, Corman ML, Nugent FW, Veidenheimer MC. Anal Complications in Crohn’s disease. Dis Colon Rectum 1981;24:22–4
   PubMed Web of Science ®Google Scholar
• Hellers G, Bergstrand O, Ewerth S, Holmstrom B. Occurrence and outcome after primary treatment of anal fistulae in Crohn’s disease. Gut 1980;21:525–7
   PubMed Web of Science ®Google Scholar
• Wiese DM, Schwartz DA. Managing Perianal Crohn’s disease. Curr Gastroenterol Rep 2012;14:153–61
   PubMedGoogle Scholar
• Schwartz DA, Loftus EV, Tremaine WJ, Panaccione R, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of fistulizing Crohn’s disease in Olmsted County, Minnesota. Gastroenterology 2002;122:875–80
   PubMed Web of Science ®Google Scholar
• Tang LY, Rawsthorne P, Bernstein CN. Are perineal and luminal fistulas associated in Crohn’s disease? a population-based study. Clin Gastroenterol Hepatol 2006;4:1130–4
   PubMed Web of Science ®Google Scholar
• Ruffolo C, Citton M, Scarpa M, Angriman I, Massani M, Caratozzolo E, Bassi N. Perianal Crohn’s disease: is there something new? World J Gastroenterol 2011;17:1939–46
   Google Scholar
• Schwartz DA, Pemberton JH, Sandborn WJ. Diagnosis and Treatment of Perianal Fistulas in Crohn Disease. Ann Intern Med 2001;135:906–18
   PubMedGoogle Scholar
• Peyrin-Biroulet L, Loftus EV, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Perianal Crohn’s disease findings other than fistulas in a population-based cohort. Inflamm Bowel Dis 2012;18(1):43–8
   PubMed Web of Science ®Google Scholar
• Parks AG, Gordon PH, Hardcastle JD. A classification of fistula-in-ano. Br J Surg 1976;63:1–12
   PubMed Web of Science ®Google Scholar
• Irvine EJ. Usual therapy improves perianal Crohn’s disease as measured by a new disease activity index. J Clin Gastroenterol 1995;20:27–32
   PubMed Web of Science ®Google Scholar
• Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 1999;340:1398–405
   PubMed Web of Science ®Google Scholar
• Steele SR. Operative management of Crohn’s disease of the colon including anorectal disease. Surg Clin North Am 2007;87:611–31
   Google Scholar
• Schwartz DA, Wiersema MJ, Dudiak KM, Fletcher JG, Clain JE, Tremaine WJ, et al. A comparison of endoscopic ultrasound, magnetic resonance imaging, and exam under anesthesia for evaluation of Crohn’s perianal fistulas. Gastroenterology 2001;121:1064–72
   PubMed Web of Science ®Google Scholar
• Schratter-Sehn AJ, Lochs H, Vogelsang H, Schurawitzki H, Herold C, Schratter M. Endoscopic ultrasonography versus computed tomography in the differential diagnosis of perianorectal complications in Crohn’s disease. Endoscopy 1993;25:582–6
   PubMed Web of Science ®Google Scholar
• Berliner L, Redmond P, Purow E, Megna D, Sottile V. Computed tomography in Crohn’s disease. Am J Gastroenterol 1982;77:548–53
   Google Scholar
• Ardizzone S, Maconi G, Cassinotti A, Massari A, Bianchi Porro G. Imaging of perianal Crohn’s disease. Dig Liver Dis 2007;39:970–8
   PubMedGoogle Scholar
• Ruffolo C, Scarpa M, Faggian D, Romanato G, De Pellegrin A, Filosa T, et al. Cytokine network in chronic perianal CD and indeterminate colitis after colectomy. J Gastrointest Surg 2007;11:16–21
   Google Scholar
• Ruffolo C, Scarpa M, Faggian D, Pozza A, Navaglia F, D’Incà R, et al. Cytokine network in rectal mucosa in perianal Crohn’s disease: relations with inflammatory parameters and need for surgery. Inflamm Bowel Dis 2008;14:1406–12
   PubMedGoogle Scholar
• Ursing B, Kamme C. Metronidazole for Crohn’s disease. Lancet 1975;1:775–7
   PubMed Web of Science ®Google Scholar
• Bernstein LH, Frank MS, Brandt LJ, Boley SJ. Healing of perineal Crohn’s disease with metronidazole. Gastroenterology 1980;79:357–65
   PubMed Web of Science ®Google Scholar
• Brandt LJ, Bernstein LH, Boley SJ, Frank MS. Metronidazole therapy for perineal Crohn’s disease: a follow-up study. Gastroenterology 1982;83:383–7
   PubMed Web of Science ®Google Scholar
• Jakobovits J, Schuster M. Metronidazole therapy for Crohn’s disease and associated fistulae. Am J Gastroenterol 1984;79:533–40
   PubMed Web of Science ®Google Scholar
• Turunen U, Farkkila M, Seppala K. Long-term treatment of peri-anal or fistulous Crohn’s disease with ciprofloxacin. Scand J Gastroenterol Suppl 1989;24:144
   Google Scholar
• Korelitz BI, Present DH. Combination ciprofloxacin and metronidazole in severe perineal Crohn’s disease. Can J Gastroenterol 1993;7:571–3
   Google Scholar
• Thia KT, Mahadevan U, Feagan BG, Wong C, Cockeram A, Bitton A, et al. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn’s disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis 2009;15:17–24
   PubMed Web of Science ®Google Scholar
• Dejaco C, Harrer M, Waldhoer T, Miehsler W, Vogelsang H, Reinisch W. Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn’s disease. Aliment Pharmacol Ther 2003;18:1113–20
   PubMed Web of Science ®Google Scholar
• West RL, Van der Woude CJ, Hansen BE, Felt-Bersma RJ, van Tilburg AJ, Drapers JA, Kuipers EJ. Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn’s disease with infliximab: a double-blind placebo-controlled study. Aliment Pharmacol Ther 2004;20:1329–36
   PubMed Web of Science ®Google Scholar
• West RL, Van der Woude CJ, Endtz H, Hansen BE, Ouwedijk M, Boelens HA, et al. Perianal fistulas in Crohn’s disease are predominately colonized by skin flora: implications for antibiotic treatment? Dig Dis Sci 2005;50:1260–3
   PubMed Web of Science ®Google Scholar
• Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-Mercaptopurine in Crohn disease: a meta-analysis. Ann Intern Med 1995;122:132–42
   Google Scholar
• Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn’s disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980;302:981–7
   PubMed Web of Science ®Google Scholar
• Sandborn WJ. A critical review of cyclosporine therapy in inflammatory bowel disease. Inflamm Bowel Dis 1995;1:48–63
   Google Scholar
• McDonald JW, Feagan BG, Jewell D, Brynskov J, Stange EF, Macdonald JK. Cyclosporine for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 2005;2:CD000297
   Google Scholar
• Egan LJ, Sandborn WJ, Tremaine WJ. Clinical outcome following treatment of refractory inflammatory and fistulizing CD with intravenous cyclosporine. Am J Gastroenterol 1998;93:442–8
   PubMed Web of Science ®Google Scholar
• Lowry PW, Weaver AL, Tremaine WJ, Sandborn WJ. Combination therapy with oral tacrolimus (FK 506) and azathioprine or 6-mercaptopurine for treatment refractory Crohn’s disease perianal fistulae. Inflamm Bowel Dis 1999;5:239–45
   PubMed Web of Science ®Google Scholar
• Ierardi E, Principi M, Rendina M, Francavilla R, Ingrosso M, Pisani A, et al. Oral tacrolimus (FK 506) in Crohn’s disease complicated by fistulae of the perineum. J Clin Gastroenterol 2000;30:200–2
   Google Scholar
• Fellermann K, Ludwig D, Stahl M, David-Walek T, Stange EF. Steroid unresponsive acute attacks of inflammatory bowel disease: immunomodulation by Tacrolimus. Am J Gastroenterol 1998;93:1860–6
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Present DH, Isaacs KL, Wolf DC, Greenberg E, Hanauer SB, et al. Tacrolimus for the treatment of fistulas in patients with Crohn’s disease: a randomized, placebo-controlled trial. Gastroenterology 2003;125:380–8
   PubMed Web of Science ®Google Scholar
• Yang Soon S, Ansari A, Yaneza M, Raoof S, Hirst J, Sanderson JD. Experience with the use of low-dose methotrexate for inflammatory bowel disease. Euro J Gastroenterol Hepatol 2004;16:921–6
   Google Scholar
• Korzenik JR, Dieckgraefe BK, Valentine JF, Hausman DF, Gilbert MJ; Sargramostim in Crohn’s Disease Study Group. Sargramostim for active Crohn’s Disease. N Engl J Med 2005;352:2193–201
   PubMed Web of Science ®Google Scholar
• Wenzl HH, Hinterleitner TA, Aichbichler BW, Fickert P, Petritsch W. Mycophenolate mofetil for Crohn’s Disease: short-term efficacy and long-term outcome. Aliment Pharmacol Ther 2004;19:427–34
   PubMed Web of Science ®Google Scholar
• Plamondon S, Ng SC, Kamm MA. Thalidomide in luminal and fistulizing Crohn’s disease resistant to standard therapies. Aliment Pharmacol Ther 2007;25:557–67
   PubMed Web of Science ®Google Scholar
• Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systemic review and meta-analysis. Am J Gastroenterol 2011;106:644–59
   PubMed Web of Science ®Google Scholar
• Knight DM, Trinh H, Le J. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993;30:1443–53
   PubMed Web of Science ®Google Scholar
• Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 2004;350:876–85
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing crohn’s disease. Gastroenterology 2005;128:862–9
   PubMed Web of Science ®Google Scholar
• Sands BE, Blank MA, Patel K, Van Deventer SJ. Long-term treatment of rectovaginal fistulas in CD: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol 2004;2:912–20
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in CD: the CLASSIC-I trial. Gastroenterology 2006;130:323–33
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007;146:829–38
   PubMed Web of Science ®Google Scholar
• Colombel JF, Schwartz DA, Sandborn WJ, Kamm MA, D’Haens G, Rutgeerts P, et al. Adalimumab for the treatments of fistulas in patients with Crohn’s disease. Gut 2009;58:940–8
   PubMed Web of Science ®Google Scholar
• Panaccione R, Colombel JF, Sandborn WJ, Rutgeerts P, D’Haens GR, Robinson AM, et al. Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn’s disease. Aliment Pharmacol Ther 2010;31:1296–309
   PubMed Web of Science ®Google Scholar
• Lichtiger S, Binion DG, Wolf DC, Present DH, Bensimon AG, Wu E, et al. The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn’s disease who failed prior infliximab therapy. Aliment Pharmacol Ther 2010;32:1228–39
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, et al. Certolizumab pegol for the treatment of Crohn’s Disease. N Engl J Med 2007;357:228–38
   PubMed Web of Science ®Google Scholar
• Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OØ, Hanauer SB, Bloomfield R, et al. Maintenance therapy with certolizumab pegol for CD. N Engl J Med 2007;357:239–50
   PubMed Web of Science ®Google Scholar
• Schreiber S, Lawrence IC, Thomsen OO, Hanauer SB, Bloomfield R, Sandborn WJ. Randomised clinical trial: certolizumab pegol for fistulas in Crohn’s disease- subgroup results from a placebo-controlled study. Aliment Pharmacol Ther 2011;33:185–93
   PubMed Web of Science ®Google Scholar
• Bouquen G, Siproudhis L, Gizard E, Wallenhorst T, Billioud V, Bretagne JF, et al. Long-term outcome of perianal fistulizing Crohn’s disease treated with infliximab. Clin Gastroenterol Hepatol 2013;8:975–81
   Google Scholar
• Sandborn WJ, Feagan BG, Rutgeerts PR, Hanauer S, Colombel JF, Sands BE, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 2013;369:711–21
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med 2012;367:1519–28
   PubMed Web of Science ®Google Scholar
• Boland BS, Sandborn WJ, Chang JT. Update on janus kinase antagonists in inflammatory bowel disease. Gastronenterol Clin North Am 2014;43:603–17
   PubMed Web of Science ®Google Scholar
• Ford AC, Luthra P, Hanauer SB, Travis SP, Harris MS, Reinisch W. Placebo response rate in clinical trials of fistulizing Crohn’s disease: systemic revew and meta-analysis. Clin Gastroenterol Hepatol 2014;12:1981–90
   Google Scholar
• Buchmann P, Keighley MR, Allan RN, Thompson H, Alexander-Williams J. Natural history of perianal CD. Ten year follow-up: a plea for conservatism. Am J Surg 1980;140:642–4
   PubMed Web of Science ®Google Scholar
• Singh B, McC Mortensen NJ, Jewell DP, George B. Perianal CD. Br J Surg 2004;91:801–14
   Google Scholar
• Keighley MR, Allan RN. Current status and influence of operation on perianal Crohn’s disease. Int J Colorectal Dis 1986;1:104–7
   Google Scholar
• Michelassi F, Melis M, Rubin M, Hurst RD. Surgical treatment of anorectal complications in Crohn’s disease. Surgery 2000;128:597–603
   PubMed Web of Science ®Google Scholar
• Regueiro M, Mardini H. Treatment of perianal fistulizing Crohn’s disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement. Inflamm Bowel Dis 2003;9:98–103
   PubMed Web of Science ®Google Scholar
• Topstad DR, Panaccione R, Heine JA, Johnson DR, MacLean AR, Buie WD. Combined seton placement, infliximab infusion and maintenance immunosuppressive improve healing rate in fistulizing anorectal Crohn’s disease: a single center experience. Dis Colon Rectum 2003;46:577–83
   PubMed Web of Science ®Google Scholar
• Schwartz DA, White CM, Wise PE, Herline AJ. Use of endoscopic ultrasound to guide combined medical and surgical therapy for patients with Crohn’s perianal fistulas. Inflamm Bowel Dis 2005;11:727–32
   PubMed Web of Science ®Google Scholar
• Wolkomir AF, Luchtefeld MA. Surgery for symptomatic hemorrhoids and anal fissures in CD. Dis Colon Rectum 1993;36:545–7
   Google Scholar
• Alexander-Williams J, Steinberg DM, Fielding JS, Thompson H, Cooke WT. Proceedings: perianal Crohn’s disease. Gut 1974;15:822–3
   Google Scholar
• Swinscoe MT, Ventakasubramaniam AK, Jayne DG. Fibrin glue for fistula-in-ano: the evidence reviewed. Tech Coloproctol 2005;9:89–94
   Google Scholar
• Vitton V, Gasmi M, Barthet M, Desjeux A, Orsoni P, Grimaud JC. Long-term healing of Crohn’s anal fistulas with fibrin glue injection. Aliment Pharmacol Ther 2005;21:1453–7
   PubMedGoogle Scholar
• Cestaro G, De Rosa M, Gentile M. Treatment of fistula in ano with fibrin glue: preliminary results from a prospective study. Minerva Chir 2014;69:225–8
   Google Scholar
• Atienza P, Ksiaa M. Particular aspects of proctology for anoperineal lesions in Crohn’s disease. J Visc Surg 2015. [Epub ahead of print]
   Google Scholar
• Cintron JR, Abcarian H, Chaudry V, Singer M, Hunt S, Birnbaum E, et al. Treatment of fistula-in-ano using a porcine small intestinal submucosa anal fistula plug. Tech Coloproctol 2013;17:187–91
   Google Scholar
• Marchesa P, Hull TL, Fazio VW. Advancement sleeve flaps for treatment of severe perianal Crohn’s disease. Br J Surg 1998;85:1695–8
   PubMed Web of Science ®Google Scholar
• Hull TL, Fazio VW. Surgical approaches to low anovaginal fistula in Crohn’s disease. Am J Surg 1997;173:95–8
   Google Scholar
• Madoff RD, Fleshman JW. AGA technical review on the diagnosis and care of patients with anal fissure. Gastroenterology 2003;124:235–45
   PubMedGoogle Scholar
• Fleshner PR, Schoetz DJJr, Roberts PL, Murray JJ, Coller JA, Veidenheimer MC. Anal fissure in Crohn’s disease: a plea for aggressive management. Dis Colon Rectum 1995;38:1137–43
   Google Scholar
• Jonas M, Scholefield JH. Anal fissure. Gastroenterol Clin North Am 2001;30:167–81
   Google Scholar
• Jeffery PJ, Parks AG, Ritchie JK. Treatment of Haemorrhoids in patients with inflammatory bowel disease. Lancet 1977;1:1084–5
   PubMed Web of Science ®Google Scholar
• Mukta V, Rocco R. Anal stenosis. Surg Clin North Am 2010;90:137–45
   Google Scholar
• Wolkomir AF, Luchtefeld MA. Surgery for symptomatic hemorrhoids and anal fissures in Crohn’s disease. Dis Colon Rectum 1993;36:545–7
   Google Scholar
• Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB; American Gastroenterological Association Clinical Practice Committee. AGA technical review on perianal Crohn’s Disease. Gastroenterology 2003;125:1508–30
   PubMed Web of Science ®Google Scholar
• Steele SR. Operative management of Crohn’s Disease of the colon including anorectal disease. Surg Clin North Am 2007;87:611–31
   Google Scholar
• Schwartz DA. What is the optimal maintenance treatment for perianal Crohn’s disease? Inflamm Bowel Dis 2008;14:S269–70
   Google Scholar
• Van Assche G, Vanbeckevoort D, Bielen D, Coremans G, Aerden I, Noman M, et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn’s disease. Am J Gastroenterol 2003;98:332–9
   PubMed Web of Science ®Google Scholar
• Guidi L, Ratto C, Semeraro Roberto I, De Vitis I, Papa A, et al. Combined therapy with infliximab and seton drainage for perianal fistulizing Crohn’s disease with anal endosonographic monitoring: a single-centre experience. Tech Coloproctol 2008;12:111–17
   PubMed Web of Science ®Google Scholar